SNYSanofiRunning, no new patients
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Plasma Cell Myeloma Recurrent
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 531 (final count)
- Started
- Jun 23, 2022
- Main results expected
- Nov 6, 2024
- Fully finished
- Oct 22, 2027
- Results posted
- Nov 14, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State
Measured over: Pre-dose at Cycle 6 Day 1
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05405166 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC